Kai Su1, Nadezhda S Sabeva, Yuhuan Wang, Xiaoxi Liu, Joshua D Lester, Jingjing Liu, Shuang Liang, Gregory A Graf. 1. From the Department of Pharmaceutical Sciences, Graduate Center for Nutritional Sciences and Saha Cardiovascular Research Center, University of Kentucky, Lexington (K.S., Y.W., X.L., J.D.L., G.A.G.); Department of Neuroscience, Universidad Central del Caribe, Bayamon, Puerto Rico (N.S.S.); Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas (J.L.); and Department of Clinical Laboratories, Jinshan Branch of the Sixth People's Hospital of Shanghai, Shanghai, China (S.L.).
Abstract
OBJECTIVE: Recent studies support a role for cholesterol in the development of obesity and nonalcoholic fatty liver disease. Mice lacking the ABCG5 ABCG8 (G5G8) sterol transporter have reduced biliary cholesterol secretion and are more susceptible to steatosis, hepatic insulin resistance, and loss of glycemic control when challenged with a high-fat diet. We hypothesized that accelerating G5G8-mediated biliary cholesterol secretion would correct these phenotypes in obese mice. APPROACH AND RESULTS: Obese (db/db) male and their lean littermates were administered a cocktail of control adenovirus or adenoviral vectors encoding ABCG5 and ABCG8 (AdG5G8). Three days after viral administration, measures of lipid and glucose homeostasis were determined, and tissues were collected for biochemical analyses. AdG5G8 increased biliary cholesterol and fecal sterol elimination. Fasting glucose and triglycerides declined, and glucose tolerance improved in obese mice expressing G5G8 compared with mice receiving control adenovirus. These changes were associated with a reduction in phosphorylated eukaryotic initiation factor 2α and c-Jun N-terminal kinase in liver, suggesting alleviation of endoplasmic reticulum stress. Phosphorylated insulin receptor and protein kinase B were increased, indicating restored hepatic insulin signaling. However, there was no reduction in hepatic triglycerides after the 3-day treatment period. CONCLUSIONS: Accelerating biliary cholesterol secretion restores glycemic control and reduces plasma triglycerides in obese db/db mice.
OBJECTIVE: Recent studies support a role for cholesterol in the development of obesity and nonalcoholic fatty liver disease. Mice lacking the ABCG5ABCG8 (G5G8) sterol transporter have reduced biliary cholesterol secretion and are more susceptible to steatosis, hepatic insulin resistance, and loss of glycemic control when challenged with a high-fat diet. We hypothesized that accelerating G5G8-mediated biliary cholesterol secretion would correct these phenotypes in obesemice. APPROACH AND RESULTS:Obese (db/db) male and their lean littermates were administered a cocktail of control adenovirus or adenoviral vectors encoding ABCG5 and ABCG8 (AdG5G8). Three days after viral administration, measures of lipid and glucose homeostasis were determined, and tissues were collected for biochemical analyses. AdG5G8 increased biliary cholesterol and fecal sterol elimination. Fasting glucose and triglycerides declined, and glucose tolerance improved in obesemice expressing G5G8 compared with mice receiving control adenovirus. These changes were associated with a reduction in phosphorylated eukaryotic initiation factor 2α and c-Jun N-terminal kinase in liver, suggesting alleviation of endoplasmic reticulum stress. Phosphorylated insulin receptor and protein kinase B were increased, indicating restored hepatic insulin signaling. However, there was no reduction in hepatic triglycerides after the 3-day treatment period. CONCLUSIONS: Accelerating biliary cholesterol secretion restores glycemic control and reduces plasma triglycerides in obese db/db mice.
Authors: Scott W Altmann; Harry R Davis; Li-Ji Zhu; Xiaorui Yao; Lizbeth M Hoos; Glen Tetzloff; Sai Prasad N Iyer; Maureen Maguire; Andrei Golovko; Ming Zeng; Luquan Wang; Nicholas Murgolo; Michael P Graziano Journal: Science Date: 2004-02-20 Impact factor: 47.728
Authors: Gregory A Graf; Wei-Ping Li; Robert D Gerard; Ingrid Gelissen; Ann White; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Invest Date: 2002-09 Impact factor: 14.808
Authors: Gregory A Graf; Liqing Yu; Wei-Ping Li; Robert Gerard; Pamela L Tuma; Jonathan C Cohen; Helen H Hobbs Journal: J Biol Chem Date: 2003-09-22 Impact factor: 5.157
Authors: Liqing Yu; Robert E Hammer; Jia Li-Hawkins; Klaus Von Bergmann; Dieter Lutjohann; Jonathan C Cohen; Helen H Hobbs Journal: Proc Natl Acad Sci U S A Date: 2002-11-20 Impact factor: 11.205
Authors: Khoi Q Tran; Shannon J Graewin; Deborah A Swartz-Basile; Attila Nakeeb; Carol L Svatek; Henry A Pitt Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: Yuhuan Wang; Kai Su; Nadezhda S Sabeva; Ailing Ji; Deneys R van der Westhuyzen; Fabienne Foufelle; Xia Gao; Gregory A Graf Journal: Metabolism Date: 2015-08-15 Impact factor: 8.694
Authors: Paul F Lebeau; Jae Hyun Byun; Khrystyna Platko; Ali A Al-Hashimi; Šárka Lhoták; Melissa E MacDonald; Aurora Mejia-Benitez; Annik Prat; Suleiman A Igdoura; Bernardo Trigatti; Kenneth N Maclean; Nabil G Seidah; Richard C Austin Journal: JHEP Rep Date: 2019-11-05